Abstract Objective To synthesize the current preclinical and clinical evidence on the utility and potential mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a therapeutic strategy for major ophthalmic diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration
If we accept this argument and also accept that metformin, despite inhibiting mTOR, is not a CRM (77, 78) then metformin would not be expected to extend lifespan
These three symptoms are confusing for a reason: fatigue is a listed GLP-1 side effect, cycle shifts often follow weight change itself, and hot flashes are common in perimenopause with or without medication
Comparing Retatrutide to Other Weight Loss Medications Retatrutide's triple-receptor targeting sets it apart from existing weight loss therapies: Semaglutide (Wegovy) : A GLP-1 receptor agonist associated with an average weight loss of approximately 15% after 68 weeks
While GLP-1 medications are generally well-tolerated, it's important to be aware of the potential side effects that may occur